Verona Pharma PLC Notice of GM

 
TIDMVRP 
 
Verona Pharma plc 
 
                      ("Verona Pharma" or the "Company") 
 
                     Confirmation of General Meeting Date 
 
1 July 2016, Cardiff - Verona Pharma plc (AIM: VRP), the drug development 
company focused on first-in-class medicines to treat respiratory diseases, 
confirms that, further to the Notice of Meeting contained within the Circular 
posted to Shareholders on 17 June 2016 in relation to the Proposed Placing, the 
General Meeting of the Company will be held at 11.00 a.m. on 22 July 2016 at 
the offices of Shakespeare Martineau LLP whose address as of 18 July 2016 is 
Allianz House, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR. 
 
Capitalised terms in this announcement have the same meaning as in the Circular 
being published in conjunction with the proposed placing. 
 
The expected timetable of principal events remains as previously stated, 
namely: 
 
Latest time and date for receipt of completed 
Forms of Proxy to be valid at the General Meeting           11.00 a.m. on 20 July 
                                                                             2016 
 
 
General Meeting                                             11.00 a.m. on 22 July 
                                                                             2016 
 
 
Announcement of results of General Meeting                           22 July 2016 
 
 
Admission to trading and commencement of dealings                    29 July 2016 
in the Placing Shares on AIM 
 
 
Despatch of definitive share certificates for Placing           by 16 August 2016 
Shares 
in certificated form 
 
Despatch of definitive certificates for Warrants                by 16 August 2016 
 
Notes: 
 
(1)        References to times are to London time (unless otherwise stated). 
 
(2)        If any of the above times or dates should change, the revised times 
and/or dates will be notified by an announcement to an RIS and otherwise 
communicated to Placees. 
 
(3)        Certain of the events in the above timetable are conditional upon, 
amongst other things, the approval of the Resolutions to be proposed at the 
General Meeting. 
 
(4)        The Warrants will not be separately admitted to trading on AIM, but 
the Warrant Shares which will arise following any valid exercise of Warrants 
will be admitted to trading in due course as part of the single class of shares 
admitted to trading on AIM. 
 
-Ends- 
 
For further information please contact: 
 
Verona Pharma plc                      Tel: +44 (0)20 3283 4200 
 
Jan-Anders Karlsson, Chief Executive 
Officer 
 
N+1 Singer                             Tel: +44 (0)20 7496 3000 
 
Aubrey Powell / Jen Boorer 
 
FTI Consulting                         Tel: +44 (0)20 3727 1000 
 
Simon Conway/Stephanie Cuthbert 
 
Notes to Editors 
 
About Verona Pharma plc 
 
Verona Pharma plc is a UK-based clinical stage biopharmaceutical company 
focused on the development of innovative prescription medicines to treat 
respiratory diseases with significant unmet medical needs, such as chronic 
obstructive pulmonary disease (COPD), asthma and cystic fibrosis. 
 
Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in phase 
II trials as a nebulised treatment for acute exacerbations of COPD in the 
hospital setting.  The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and 
therefore has both bronchodilator and anti-inflammatory effects, which are 
essential to the improvement of patients with COPD and asthma. 
 
Verona Pharma is also building a broader portfolio of RPL554-containing 
products to maximise its benefit to patients and its value.  This includes the 
very significant markets for COPD and asthma maintenance therapy.  The Company 
is also exploring the potential of the drug in different diseases, such as 
cystic fibrosis, where it is in pre-clinical testing and has recently received 
a Venture and Innovation Award from the Cystic Fibrosis Trust. 
 
About Chronic Obstructive Pulmonary Disease (COPD) 
 
Sixty-five million people worldwide suffer from moderate to severe COPD and the 
World Health Organisation (WHO) expects COPD to be the 3rd leading cause of 
death globally by 2020.  It is the only major chronic disease with increasing 
mortality.  Currently available drugs are aimed at long-term maintenance 
therapy, with the market dominated by large pharma.  Despite the wide 
availability of these therapies, COPD patients suffer acute periods of 
worsening symptoms (exacerbations), which cause, in the US alone, some 1.5 
million A&E visits, 726,000 hospitalisations and 120,000 deaths per annum. 
 
Bronchodilating therapy is considered to be the standard of care, and agents 
can be administered via handheld devices such as metered dose inhaler (MDI), 
dry powder inhaler (DPI) and by nebulisers.  The nebulised bronchodilator 
market was worth about $1 billion in 2014 in the US.1  RPL554 is being 
developed by Verona Pharma as an add-on therapy to the "Standard of Care" with 
the objectives of providing rapid and pronounced improvement in lung function, 
reduced symptoms and both shortened duration of hospital stays and reduced 
re-admission rates 30 days after discharge from hospital.  Studies to date on 
RPL554 have demonstrated that it has a strongly differentiated 3-way mode of 
action, being: (1) bronchodilation (the relaxation of smooth muscle in the 
airway); (2) anti-inflammatory effects on cells and (3) ion channel activation 
in epithelial cells, with increased mucociliary clearance of the airway. 
 
1 IMS Consulting Group market research 2014 
 
 
 
END
(END) Dow Jones Newswires
July 01, 2016 03:00 ET (07:00 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024